CGM

CompuGroup Medical US announces CEO transition

Retrieved on: 
Wednesday, March 27, 2024
CGM, Acquisition, LIS, Electronic health record, Clearing house, Management

In the past three years, CompuGroup Medical US has achieved excellent profitable growth, partly as a result of the launch of converting its APRIMA customers to CGM's inhouse Clearinghouse eMEDIX.

Key Points: 
  • In the past three years, CompuGroup Medical US has achieved excellent profitable growth, partly as a result of the launch of converting its APRIMA customers to CGM's inhouse Clearinghouse eMEDIX.
  • "We are very grateful for Derek Pickell's leadership and contributions to CompuGroup Medical US", said Michael Rauch, CEO of CompuGroup Medical SE & Co. KGaA.
  • Derek Pickell, the outgoing US CEO, has led CompuGroup Medical US with distinction, overseeing steady growth and expansion.
  • Benedikt Brueckle has been with CompuGroup Medical for more than 13 years and led the acquisition of eMDs in 2020.

EQS-News: CGM plans to double its dividend

Retrieved on: 
Wednesday, March 13, 2024
CGM, Annual report, XETRA, EUR, News, Annual

The general partner of CompuGroup Medical SE & Co. KGaA (CGM) intends to sustainably increase the dividend to a higher level, and will therefore propose a dividend of EUR 1.00 per share to the Annual General Meeting for the financial year 2023.

Key Points: 
  • The general partner of CompuGroup Medical SE & Co. KGaA (CGM) intends to sustainably increase the dividend to a higher level, and will therefore propose a dividend of EUR 1.00 per share to the Annual General Meeting for the financial year 2023.
  • Based on the 52.2 million shares currently entitled to a dividend payment, the planned total payout would double to EUR 52.2 million (previous year: EUR 26.1 million).
  • Based on the year-end closing price for 2023 (Xetra closing price on December 29, 2023: EUR 37.90), this proposal corresponds to a dividend yield of 2.6 percent.
  • Based on the final financial results for the financial year, the general partner and the supervisory board will decide on their final dividend proposal to the general meeting.

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Retrieved on: 
Monday, March 4, 2024
Incidence, CGM, Doctor of Philosophy, Level 2, MD, FDA, Quality of life, IROS, Safety, Diabetes, Therapy, Type 2 diabetes, Patient, Insulin, T1D, Pharmaceutical industry

This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.

Key Points: 
  • This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.
  • The Phase 3 study will assess two doses of orally administered cadisegliatin versus placebo in patients currently being treated with multiple daily insulin injections and continuous subcutaneous insulin infusion, who use a continuous glucose monitor (CGM).
  • The primary efficacy endpoint of the study will compare the incidence of Level 2 or Level 3 hypoglycemic events between cadisegliatin-treated subjects and those in the placebo group.
  • Cadisegliatin is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes

Retrieved on: 
Friday, March 8, 2024
Health, Medical Devices, Diabetes, Health Technology, General Health, Research, Science, T2D, CGM, Conference, Fortezza, Patient, T1D, Medical device

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”) in Florence, Italy.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”) in Florence, Italy.
  • We are pleased the data shows high satisfaction scores, improved diabetes distress scores, and no evidence that repeated insertions and removals impact satisfaction,” said Francine Kaufman, M.D., Chief Medical Officer of Senseonics.
  • “As patients and providers consider the best options to help manage diabetes, presenting this additional compelling data continues to raise the awareness of the benefits of Eversense.
  • The DDS-17 (a questionnaire designed to measure four critical dimensions of distress with diabetes: emotional burden, regimen distress, interpersonal distress and physician distress) was administered to participants at the start of the study.

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Retrieved on: 
Friday, March 8, 2024
Research, General Health, Technology, Medical Devices, Other Manufacturing, Health Technology, Clinical Trials, Science, Biotechnology, Wearables, Mobile Technology, Health, Diabetes, Manufacturing, TIR, Dexcom, CGM, Doctor of Philosophy, Randomized controlled trial, MD, Treatment, Medical director, G6, AID, Intervention, Conference, ATTD, Safety, Hypoglycemia, Control, RCT, T1D, Corporation, DKA, Body mass index, Treatment and control groups, Pharmaceutical industry

The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.

Key Points: 
  • The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
  • "Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard.
  • The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6.
  • In conclusion, this multi-national, RCT data demonstrates the superiority of the Omnipod 5 AID System compared to standard pump therapy with CGM and indicates that it should be offered as a first-line therapy for adults with type 1 diabetes.

New Report: People Living with Diabetes Have False Hope in GLP-1s, Strong Demand for More Engagement and Education

Retrieved on: 
Thursday, March 7, 2024
Practice Management, Pharmaceutical, Managed Care, Medical Supplies, General Health, Health, Diabetes, Other Health, Obesity, CCS, Conditional sentence, Silver, CGM, Self-management, Attitude, Hope, Education, Patient, Pharmaceutical industry

“GLP-1 weight loss drugs alone are not a silver bullet when it comes to improving the health and well-being of those living with diabetes,” said Dr. Arti Masturzo, Chief Medical Officer at CCS.

Key Points: 
  • “GLP-1 weight loss drugs alone are not a silver bullet when it comes to improving the health and well-being of those living with diabetes,” said Dr. Arti Masturzo, Chief Medical Officer at CCS.
  • Many of these same respondents stressed the value of additional clinical touchpoints to manage their diabetes.
  • At times, infrequent patient engagement and a lack of proper education and coaching can contribute to patients with diabetes facing dangerous and costly health issues.
  • Of that group, 82% also said that the emergency could have been prevented with better support in the management of their diabetes.

Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference

Retrieved on: 
Wednesday, March 6, 2024
Health, Communications, Medical Devices, Diabetes, Health Technology, General Health, Public Relations, Investor Relations, Interest, CGM, Medtech, Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
  • Management is scheduled to participate on Wednesday, March 13, 2024, at 12:00pm ET and will hold one-on-one meetings following.
  • Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Retrieved on: 
Wednesday, March 6, 2024
Technology, General Health, Health, Hardware, MARD, American Diabetes Association, Algorithm, CGM, Know Labs, Treatment, FDA, Blood, Dielectric spectroscopy, Data, Conference, Type 2 diabetes, ATTD, Type 2, Mayo Clinic, Clinical professor, Prediabetes, Clinical trial, RF, CWD, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
  • Dr. Virend K. Somers of the Mayo Clinic serves as an author and co-investigator on the clinical research protocol.
  • “Despite significant efforts in the development of non-invasive blood glucose monitoring solutions, delivering a highly accurate, economical, FDA-cleared non-invasive continuous glucose monitor (CGM) still remains to be seen.
  • On the held-out test dataset, blood glucose was estimated with a MARD of 11.1 ± 2.1% relative to venous blood.

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
Tuesday, March 5, 2024
Software, Health, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Tandem, HCP, CGM, Apple Watch, G6, Diabetic ketoacidosis, AID, DXCM, G7, Hypoglycemia, GLP1, Conference, Type 2 diabetes, ATTD, Type 2, Patient, Insulin, Apple, Mortality, Pharmaceutical industry

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, March 5, 2024
Health Technology, Diabetes, Manufacturing, Technology, Pharmaceutical, Other Consumer, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Manufacturing, Science, Consumer, Health, Research, Real-World Evidence, Cloud, OBE, Adolescence, Doctor of Philosophy, Treatment, Medical director, Database, University, Hypoglycemia, Associate, AID, University of Liverpool, Standard of care, Data, Therapy, Insulin, Convention, Randomized controlled trial, CGM, Pathway, Use, Conference, MDI, Automation, Endocrinology, MD, DASH, ATTD, Medicare, University of Edinburgh, Edge Hill University, Corporation, Chairperson, Medical device

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.